<110> Applied Research Systems ARS holding N.V.

<120> NOVEL ANTAGONISTS OF CXCR3 BINDING CXC CHEMOKINES

<130> WO513

<160> 8

<170> PatentIn version 3.0

<210> 1

<211> 73

<212> PRT

<213> Homo sapiens

<400> 1

Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys Ile Gly Pro Gly Val
1 5 10 15

Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
20 25 30

Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Lys Glu Asn
35 40 45

Lys Gly Gln Arg Cys Leu Asn Pro Lys Ser Lys Gln Ala Arg Leu Ile
50 55 60

Ile Lys Lys Val Glu Arg Lys Asn Phe
65 70

<210> 2

<211> 73

<212> PRT

<213> synthetic construct

<400> 2

Phe Pro Met Phe Ala Ala Gly Ala Cys Leu Cys Ile Gly Pro Gly Val
1 5 10 15

Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
20 25 30

Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Lys Glu Asn
35 40 45

Lys Gly Gln Arg Cys Leu Asn Pro Lys Ser Lys Gln Ala Arg Leu Ile
50 55 60

Ile Lys Lys Val Glu Arg Lys Asn Phe
65 70

<210> 3

<211> 73

<212> PRT

<213> synthetic construct

<400> 3

Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys Ile Gly Pro Gly Val
1 5 10 15

Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
20 25 30

Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Ala Glu Asn
35 40 45

Ala Gly Gln Ala Cys Leu Asn Pro Lys Ser Lys Gln Ala Arg Leu Ile
50 55 60

Ile Lys Lys Val Glu Arg Lys Asn Phe
65 70

<210> 4

<211> 73

<212> PRT

<213> synthetic construct

<400> 4

Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys Ile Gly Pro Gly Val
1 5 10 15

Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
20 25 30

Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Lys Glu Asn
35 40 45

Lys Gly Gln Arg Cys Leu Asn Pro Ala Ser Ala Gln Ala Ala Leu Ile
50 55 60

Ile Lys Lys Val Glu Arg Lys Asn Phe
65 70

<210> 5

<211> 73

<212> PRT

<213> synthetic construct

<400> 5

Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys Ile Gly Pro Gly Val
1 5 10 15

Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
20 25 30

Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Lys Glu Asn
35 40 45

Lys Gly Gln Arg Cys Leu Asn Pro 4/5s Ser Lys Gln Ala [illegible]g Leu Ile
50 55 60

Ile Ala Ala Val Glu Ala Ala Asn Phe
65 70

<210> 6

<211> 77

<212> PRT

<213> Homo sapiens

<400> 6

Val Pro Leu Ser Arg Thr Val Arg Cys Thr Cys Ile Ser Ile Ser Asn
1 5 10 15

Gln Pro Val Asn Pro Arg Ser Leu Glu Lys Leu Glu Ile Ile Pro Ala
20 25 30

Ser Gln Phe Cys Pro Arg Val Glu Ile Ile Ala Thr Met Lys Lys Lys
35 40 45

Gly Glu Lys Arg Cys Leu Asn Pro Glu Ser Lys Ala Ile Lys Asn Leu
50 55 60

Leu Lys Ala Val Ser Lys Glu Met Ser Lys Arg Ser Pro
65 70 75

<210> 7

<211> 103

<212> PRT

<213> Homo sapiens

<400> 7

Thr Pro Val Val Arg Lys Gly Arg Cys Ser Cys Ile Ser Thr Asn Gln
1 5 10 15

Gly Thr Ile His Leu Gln Ser Leu Lys Asp Leu Lys Gln Phe Ala Pro
20 25 30

Ser Pro Ser Cys Glu Lys Ile Glu Ile Ala Thr Leu Lys Asn Gly
35 40 45

Val Gln Thr Cys Leu Asn Pro Asp Ser Ala Asp Val Lys Glu Leu Ile
50 55 60

Lys Lys Trp Glu Lys Gln Val Ser Gln Lys Lys Lys Gln Lys Asn Gly
65 70 75 80

Lys Lys His Gln Lys Lys Lys Val Leu Lys Val Arg Lys Ser Gln Arg
85 90 95

Ser Arg Gln Lys Lys Thr Thr
100

<210> 8

<211> 79

<212> PRT

<213> Mus Musculus

<400> 8

Phe Leu Met Phe Lys Gln Gly Arg Cys Leu Cys Ile Gly Pro Gly Met
1 5 10 15

Lys Ala Val Lys Met Ala Glu Ile Glu Lys Ala Ser Val Ile Tyr Pro
20 25 30

Ser Asn Gly Cys Asp Lys Val Glu Val Ile Val Thr Met Lys Ala His
35 40 45

Lys Arg Gln Arg Cys Leu Asp Pro Arg Ser Lys Gln Ala Arg Leu Ile
50 55 60

Met Gln Ala Ile Glu Lys Lys Asn Phe Leu Arg Arg Gln Asn Met
65 70 75